SCHEMBL24943239

SCHEMBL24943239

COC(=O)c1ccc(OC(C)S)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.60
CA2 P00918 2/20 0.60
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
MAPT P10636 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
CA12 O43570 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
STS P08842 1/20 0.50
RAB9A P51151 3/20 0.49
NPC1 O15118 1/20 0.49
KDM4E B2RXH2 1/20 0.49
TSHR P16473 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1854840 0.85 KMT2A (0.66) CA1CA2KMT2AMEN1MAPT
SCHEMBL6548631 0.85 CA1 (0.64) CA1CA2KMT2AMEN1MAPT
SCHEMBL6285461 0.83 CA1 (0.62) CA1CA2KMT2AMEN1MAPT
SCHEMBL5156853 0.82 KMT2A (0.56) CA1CA2KMT2AMEN1MAPT
SCHEMBL6616955 0.81 CA1 (0.60) CA1CA2KMT2AMEN1MAPT
SCHEMBL27579858 0.81 KMT2A (0.71) CA1CA2KMT2ASMN1; SMN2TSHR
SCHEMBL4261434 0.80 MEN1 (0.71) CA1CA2KMT2AMEN1MAPT
SCHEMBL28583976 0.80 KMT2A (0.67) CA1CA2KMT2AMEN1MAPT
SCHEMBL28579268 0.80 KMT2A (0.67) CA1CA2KMT2AMEN1MAPT
SCHEMBL28572406 0.80 KMT2A (0.67) CA1CA2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease SHY Therapeutics LLC 2023-09-14 US disclosed
US-11560390-B2 Compounds for the treatment of cancer and inflammatory disease SHY Therapeutics LLC (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560390-B2 Compounds for the treatment of cancer and inflammatory disease MAPK6, MAP3K6, MAPK4 CA1 4238/4885CA2 4222/4885KMT2A 3544/4885
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease MAPK6, MAP3K6, MAPK4 CA1 4238/4885CA2 4222/4885KMT2A 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.